Search

Your search keyword '"Petitpain, N."' showing total 260 results
Start Over Author "Petitpain, N."
260 results on '"Petitpain, N."'

19. Pembrolizumab induced fatal myositis and myocarditis

Author

Petitpain, N., GARON, J., Degiorgis, M, Swiegot, D., Ries, F, Gillet, P, HELLE, Déborah, Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'OncoHématologie, Centre Hospitalier – Luxembourg, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

22. Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012

Author

Petitpain, N., Argoullon, L., Masmoudi, K., Fedrizzi, S., Cottin, J., Latarche, C., Mertes, P., Pierre GILLET, French Network of Regional Pharmacovigilance Centres Network, Centre Régional de PharmacoVigilance de Lorraine (CRPV Lorraine), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Centre régional de pharmacovigilance de Caen Basse-Normandie (CRPV), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Pharmacie Hospitalière et Pharmacovigilance, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France, parent, Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy] (Pôle S2R), CHU Strasbourg, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2018

25. Intracranial hemorrhage and oral anticoagulants of patients treated between 2011 and 2013 at the Nancy Regional University Hospital

Author

Leblanc, A., Petitpain, N., Pereira, O, Adssi, HE, Latarche, C., Gillet, P., Colnat-Coulbois, S., Centre Régional de PharmacoVigilance de Lorraine (CRPV Lorraine), CRHU Nancy, Direction régionale du service médical du Nord-Est, Département d'information médicale, hôpital St-Julien [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Coordination qualité risques et vigilances [CHRU de Nancy], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), and Service de Neurochirurgie [CHRU Nancy]

Subjects
Hospitals, University, Hospitalization, Anticoagulant oral, Risk Factors, [SDV]Life Sciences [q-bio], Hospitalisation, Anticoagulants, Humans, Oral anticoagulant, Intracranial hemorrhage, Hémorragie intracrânienne, Intracranial Hemorrhages, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

To perform a descriptive analysis of intracranial hemorrhages of patients treated with an antivitamin K (fluindione, acenocoumarol or warfarin) or a direct oral anticoagulant (dabigatran, rivaroxaban or apixaban) at the Nancy Regional University Hospital.The study period was from January 2011 to December 2013 and the computerized data (Programme de Médicalisation des Systèmes d'Information) of our hospital was accessed to identify the patients. Clinical data were obtained from the patients' files. Regional healthcare system was queried for reimbursement data.Among the 157 identified cases of intracranial hemorrhage, 153 were related to antivitamin K, primarily fluindione (n=127), and only 4 to a direct oral anticoagulant (3 dabigatran and 1 rivaroxaban). During the same period, regional data indicated that 65,345 patients had had at least one reimbursement of antivitamin K and 20,983 patients one reimbursement of an oral direct anticoagulant. In our series, the most frequent intracranial hemorrhages were subdural hematoma (chronic in 65 cases, acute in 50 cases) and intraparenchymal hemorrhage (20 cases). The global mortality rate was 20.2% but varied with the site of hemorrhage. In multivariate analysis, the two risk factors of fatal outcome were coma on admission (OR 6.2; 95%CI: 2.6-15.0) and a history of previous intracranial hemorrhage (OR 13,4; 95% CI: 1,6-114,9).During the 2011-2013 period, antivitamin K, especially fluindione, was the most frequently involved anticoagulants in intracranial hemorrhages with hospitalization at our Regional University Hospital. Coma on admission and a history of previous intracranial hemorrhage were the two main risk factors for fatal outcome.

Published
2017

26. TNF alpha blockers, depression and suicidality

Author

Petitpain, N., Boulanger, A, Cholle, C, Theophile, H, Bagheri, H., Gaboriau, L, Gillet, P., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

27. TNFalpha blockers, depression and suicidality

Author

Petitpain, N., Boulanger, A., Cholle, C., Theophile, H., Bagheri, H., Gaboriau, L., Pierre GILLET, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, and Centre Régional de PharmacoVigilance de Lorraine (CRPV Lorraine)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

34. Practitioners in nursing homes can also report drug adverse effects after occupational exposure

Author

Petitpain, N., Ricour, B, Swiegot, D., Becker, M., Chargois, A, Charrois-Sciaudeau, S, Gillet, P., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), and Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio], [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

35. Good use and knowledge of paracetamol among self-medicated patients: prospective study in community pharmacies

Author

Petitpain, N., Severin, A, Scala-Bertola, Julien, Latarche, Clotilde, Yelehe-Okouma, Melissa, Di Patrizio, Paolo, Gillet, Pierre, Centre Régional de PharmacoVigilance de Lorraine (CRPV Lorraine), CRHU Nancy, Service de Pharmacologie Clinique et Toxicologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Direction de la qualité [CHRU de Nancy] 54035 Nancy, Laboratoire de psychologie de l'interaction et des relations intersubjectives (INTERPSY), and Université de Lorraine (UL)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

49. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007)

Author

Sw, Dong, Pm, Mertes, Petitpain N, Hasdenteufel F, Jm, Malinovsky, and GERAP

Subjects
Drug Hypersensitivity, Latex Hypersensitivity, Data Collection, Humans, Anesthesia, France, Immunoglobulin E, Neuromuscular Blocking Agents, Intraoperative Complications, Perioperative Period, Anaphylaxis, Anti-Bacterial Agents, Skin Tests
Abstract

Hypersensitivity reactions occurring during anesthesia remain a major cause of concern for anesthesiologists. We report the results of the ninth consecutive survey of hypersensitivity reactions observed during anesthesia in France. This report will be used as an epidemiologic reference prior to this intervention.Between January 1, 2005 to December 31, 2007, 1253 patients who experienced an immune-mediated (IgE-mediated) or non-immune-mediated (non-IgE-mediated) hypersensitivity reaction were referred to one of the 40 participating centers. Diagnosis was established on the basis of clinical history, skin tests and/or specific IgE assay.An IgE-mediated or non-IgE-mediated reaction was diagnosed in 786 cases (63%) and 467 cases (37%), respectively. The most common causes of anaphylaxis were neuromuscular blocking agents (NMBA) (N.=373, 47.4%), latex (N.=158, 20%), and antibiotics (N.=141, 18.1%). Succinylcholine (N.=226, 60.6%) was the most frequently incriminated NMBA, whereas the low frequency of reactions involving cis-atracurium was confirmed (N.=22, 5.9%) when market shares of each NMBA were taken into account. An increased number of reactions involving vital dyes was recorded (N.=34, 4.4%).These changes in the epidemiology of allergic reactions confirm the need for regular epidemiologic surveys of anaphylaxis in the perioperative period.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results